Mesothelioma

We need to learn more about how to potentially lessen toxins' effects on people's lives.

Imfinzi alone or combined with Imjudo may improve survival and tumor response when administered before surgery, opening the door to neoadjuvant mesothelioma treatments.

Years after I went through mesothelioma, my husband was diagnosed with cancer, causing a reversal in the patient-caregiver roles.

After being diagnosed with mesothelioma, I learned to advocate for myself, and realized that it was an incredibly important life skill to have.

I grew up in a society where mental health was stigmatized, but cancer made me realize that it helps to speak up about these issues.

After being homebound for two years from the COVID-19 pandemic, I was eager to get out, though I did have many cancer/COVID-19 concerns.

Patients with malignant pleural mesothelioma tended to have prolonged benefit when treated with Keytruda plus Lenvima in the PEMMELA clinical trial.

I don’t fit the profile of someone who gets diagnosed with mesothelioma, so my diagnosis came as a shock.

The FDA plans to accelerate its review of IK-930, an investigational drug, for the treatment of patients with unresectable NF2-deficient malignant pleural mesothelioma, a rare cancer.

Part B of the DIONE-01 study will look at whether IOA-244 increases anti-tumor responses in expansion groups of patients.

Imfinzi plus platinum-pemetrexed chemotherapy induced survival improvements in patients with previously untreated, unresectable malignant pleural mesothelioma, compared with chemotherapy alone.

Treatment with the immunotherapy Opdivo for relapsed, malignant mesothelioma may represent a useful choice for patients with minimal therapy options.

The average survival for patients with malignant pleural mesothelioma was less than a month after being diagnosed with COVID-19, according to a small study.

Surgery for malignant pleural mesothelioma after radiotherapy may increase overall survival rates, according to a study. However, study authors note that the procedure should only be adopted in centers with substantial surgical experience.

Mesothelioma has been categorized as an “older persons” disease, writes a 14-year survivor. Which is why, she writes, her and her family were completely caught off-guard when she was diagnosed at 21.

The FDA’s approval or Opdivo (nivolumab) and Yervoy (ipilimumab) for the frontline treatment of patients with unresectable malignant pleural mesothelioma was desperately needed, says a thoracic oncologist at Memorial Sloan Kettering Cancer center. However, some questions remain.

The Food and Drug Administration’s approval of Opdivo in combination with Yervoy for patients with unresectable malignant pleural mesothelioma marks the first new systemic therapy approved in more than 15 years in this setting.

Here is a list of clinical trials that are currently happening within the mesothelioma space.

From plans to sue the School District of Philadelphia over a mesothelioma diagnosis to Dwayne “The Rock” Johnson singing for a 3-year-old with acute lymphoblastic leukemia, here’s what is making headlines in the cancer space this week.

The same properties that make certain cancers hard to treat may also promote their death by ferroptosis, scientists at the Sloan Kettering Institute have found.

A seven-year mesothelioma survivor encourages patients with cancer to be their own advocate.

A phase 3 trial compared Keytruda versus chemotherapy for patients with advanced pretreated malignant pleural mesothelioma.

Cediranib combined with platinum-based chemotherapy helped patients live longer than placebo.

A registered dietician discussed the importance of maintaining one’s weight while going through treatment for mesothelioma.

CURE® spoke with one expert about the various treatment options and current clinical trials available to patients with mesothelioma, as well as what they have to look forward to in the future.

CURE spoke with one expert about mesothelioma symptoms that patients can be on the lookout for, as well as how to be knowledgeable about certain risk factors.

Routine use of prophylactic radiotherapy in patients with malignant pleural mesothelioma is unnecessary following a chest wall procedure, according to multicenter, open-label, phase 3, randomized controlled trial findings published in the Journal of Clinical Oncology.

Results from a clinical trial in people with mesothelioma indicate that an experimental chimeric antigen receptor-T cell therapy is safe and may provide benefit to patients, especially in combination with other immunotherapies.

Maintenance therapy with defactinib failed to improve survival following front-line chemotherapy in patients with merlin-low malignant pleural mesothelioma, according to results from the phase 2 COMMAND trial.

The Food and Drug Administration has approved the NovoTTF-100L System in combination with pemetrexed and platinum-based chemotherapy for the front-line treatment of patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma.